-
10.30, 2019
Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2019（Japanese GAAP）
-
7.31, 2019
Supplementary Documents of Business Results for First Six Months of Fiscal Year 2019
読む Supplementary Documents of Business Results for First Six Months of Fiscal Year 2019
-
7.31, 2019
Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2019（Japanese GAAP）
-
4.26, 2019
Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2019（Japanese GAAP）
-
2.14, 2019
Supplementary Documents of Business Results for Fiscal Year 2018 Ending Dec. 31, 2018
読む Supplementary Documents of Business Results for Fiscal Year 2018 Ending Dec. 31, 2018
-
2.14, 2019
Non-consolidated Financial Results for the Fiscal Year Ended Dec.31,2018（Japanese GAAP）
読む Non-consolidated Financial Results for the Fiscal Year Ended Dec.31,2018（Japanese GAAP）
-
10.31, 2018
Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2018（Japanese GAAP）
-
7.31, 2018
Supplementary Documents of Business Results for First Six Months of Fiscal Year 2018
読む Supplementary Documents of Business Results for First Six Months of Fiscal Year 2018
-
7.31, 2018
Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2018（Japanese GAAP）
-
4.27, 2018
Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2018（Japanese GAAP）
-
2.14, 2018
Supplementary Documents of Business Results for Fiscal Year 2017 Ending Dec. 31, 2017
読む Supplementary Documents of Business Results for Fiscal Year 2017 Ending Dec. 31, 2017
-
2.14, 2018
Non-consolidated Financial Results for the Fiscal Year Ended Dec.31,2017（Japanese GAAP）
読む Non-consolidated Financial Results for the Fiscal Year Ended Dec.31,2017（Japanese GAAP）
-
10.31, 2017
Notice of signing a capital and business alliance agreement
読む Notice of signing a capital and business alliance agreement
-
10.31, 2017
Non-consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec.31,2017（Japanese GAAP）
-
7.31, 2017
Supplementary Documents of Business Results for First Six Months of Fiscal Year 2017 Ending Dec. 31, 2017
-
7.31, 2017
Non-consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec.31,2017（Japanese GAAP）
-
4.28, 2017
Non-consolidated Financial Results for the First Three Months of Fiscal Year Ending Dec.31,2017（Japanese GAAP）
-
2.22, 2017
Supplementary Documents of Business Results for Fiscal Year 2016 Ended Dec.31, 2016
読む Supplementary Documents of Business Results for Fiscal Year 2016 Ended Dec.31, 2016
-
2.20, 2017
Revision of Consolidated Financial Results For the Fiscal Year Ending December 31, 2016
読む Revision of Consolidated Financial Results For the Fiscal Year Ending December 31, 2016
-
2.14, 2017
Consolidated Financial Results for the Fiscal Year Ended 31 December 2016 (Japanese GAAP)
読む Consolidated Financial Results for the Fiscal Year Ended 31 December 2016 (Japanese GAAP)
-
1.10, 2017
Background of Termination Notice from Astellas of the Agreement to Co-develop ASP7374 (UM-0502) and ASP7373 (UMN-0501) and Alternative Business Plan
-
1.10, 2017
Notice Recieved from Astellas for its Excercise of Termination Right of the Agreement to Co-develop ASP7374 (UM-0502) and ASP7373 (UMN-0501)
-
1.4, 2017
Notice regarding infringement of restrictive covenants of syndicated loans for UNIGEN
読む Notice regarding infringement of restrictive covenants of syndicated loans for UNIGEN
-
10.31, 2016
Consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec. 31, 2016 (Japanese GAAP)
-
10.18, 2016
Revision of Consolidated Financial Results Forecasts For the Fiscal Year Ending December 31, 2016
読む Revision of Consolidated Financial Results Forecasts For the Fiscal Year Ending December 31, 2016
-
7.29, 2016
Supplementary Documents of Business Results for First Six Months of fiscal Year 2016 ending Dec.31, 2016
-
7.29, 2016
Consolidated Financial Results for the First Six Months of Fiscal Year Ending December 31, 2016(Japanese GAAP)
-
6.29, 2016
UMN Pharma Joins Protein Sciences’ International Zika Vaccine Consortium
読む UMN Pharma Joins Protein Sciences’ International Zika Vaccine Consortium
-
5.25, 2016
Supplementary Documents of Consolidated Financial Forecasts for Fiscal Year 2016 ending Dec.31, 2016
-
5.25, 2016
Mid-Term Business Plan FY2016－FY2019
-
4.28, 2016
Consolidated Financial Results for the First Three Months of Fiscal Year Ending December 31, 2016 (Japanese GAAP)
-
2.24, 2016
Supplementary Documents of Business Results for Fiscal Year 2015 Ended Dec.31, 2015
読む Supplementary Documents of Business Results for Fiscal Year 2015 Ended Dec.31, 2015
-
2.12, 2016
Consolidated Financial Results for the Fiscal Year Ended 31 December 2015 (Japanese GAAP)
読む Consolidated Financial Results for the Fiscal Year Ended 31 December 2015 (Japanese GAAP)
-
2.12, 2016
Protein Sciences and UNIGEN Reach Agreement to Source Flublok® Influenza Vaccine from Japan
読む Protein Sciences and UNIGEN Reach Agreement to Source Flublok® Influenza Vaccine from Japan
-
2.12, 2016
Notice regarding the capital investment in UNIGEN Gifu plant
読む Notice regarding the capital investment in UNIGEN Gifu plant
-
10.30, 2015
Consolidated Financial Results for the First Nine Months of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)
-
10.30, 2015
Revision of Consolidated Financial Results Forecasts For the Fiscal Year Ending December 31, 2015
読む Revision of Consolidated Financial Results Forecasts For the Fiscal Year Ending December 31, 2015
-
8.24, 2015
UMN Pharma relocates Yokohama Headquarters to Shin-Yokohama
-
8.3, 2015
Revised Supplement Documents for Financial Results for First half of FY 2015 Ending Dec.31, 2015
読む Revised Supplement Documents for Financial Results for First half of FY 2015 Ending Dec.31, 2015
-
7.31, 2015
Supplement Documents for Financial Results for First half of FY 2015 Ending Dec.31, 2015
読む Supplement Documents for Financial Results for First half of FY 2015 Ending Dec.31, 2015
-
7.31, 2015
Consolidated Financial Results for the First Six Months of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)
-
4.30, 2015
Consolidated Financial Results for the First Quarter of Fiscal Year Ending Dec. 31, 2015 (Japanese GAAP)
-
2.13, 2015
Supplement Documents for Financial Results for Fiscal Year 2014 Ended Dec. 31, 2014
読む Supplement Documents for Financial Results for Fiscal Year 2014 Ended Dec. 31, 2014
-
2.13, 2015
Consolidated Financial Results for the Fiscal Year Ended 31 December 2014 (Japanese GAAP)
読む Consolidated Financial Results for the Fiscal Year Ended 31 December 2014 (Japanese GAAP)
-
12.22, 2014
Protein Sciences, UMN Pharma and IHI Corporation Enter into an Agreement to Evaluate Sourcing Flublok® from Japan
-
7.31, 2014
UMN Pharma Announces Financial Results for First half of FY2014
読む UMN Pharma Announces Financial Results for First half of FY2014
-
5.30, 2014
Astellas and UMN Announce Submission of Application for Marketing Approval of Recombinant Influenza HA Vaccine ASP7374 in Japan
-
2.17, 2014
UMN Pharma Announces Financial Results for Fiscal Year 2013
読む UMN Pharma Announces Financial Results for Fiscal Year 2013
-
2.14, 2014
Daiichi Sankyo and UMN Pharma Enter into Collaborative Research Agreement for Norovirus Vaccine
読む Daiichi Sankyo and UMN Pharma Enter into Collaborative Research Agreement for Norovirus Vaccine
-
1.15, 2014
Astellas and UMN Announce Summary Results in Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)
-
10.21, 2013
Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)
-
6.11, 2013
Dr. Masahiro Michishita, Chairman & CEO of UMN Pharma, will give a presentation at Cell Culture Engineering World Asia
-
4.1, 2013
UNIGEN, a UMN Pharma subsidairy started a trial operation in Gifu Plant
読む UNIGEN, a UMN Pharma subsidairy started a trial operation in Gifu Plant
-
4.1, 2013
UMN Pharma relocates Yokohama Headquarters to Minato Mirai
読む UMN Pharma relocates Yokohama Headquarters to Minato Mirai
-
3.28, 2013
UMN Pharma Announces Change in Representative Director (CEO)
読む UMN Pharma Announces Change in Representative Director (CEO)
-
3.11, 2013
Non-inferiority Observed in Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)
読む Non-inferiority Observed in Phase III Clinical Trials of Seasonal Flu Vaccine UMN-0502(ASP7374)
-
3.6, 2013
UMN Pharma, API, and Yakult Honsha Sign Letter of Intent to Co-develop and Commercialize Biosimilars
-
1.17, 2013
U.S. FDA Approves Flublok®, the World’s First Recombinant, Highly Purified, Egg-Free Influenza Vaccine
（546KB）
-
12.18, 2012
UMN Pharma Announces Collaboration with ILDONG Pharmaceutical for Recombinant Influenza HA Vaccines in South Korea
-
12.12, 2012
Catalent and UMN Pharma announce collaboration for biosimilar development and production in Japan
読む Catalent and UMN Pharma announce collaboration for biosimilar development and production in Japan
-
12.11, 2012
Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase III Clinical Trial
読む Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase III Clinical Trial
-
12.11, 2012
UMN Pharma Stock Listed on Mothers
-
11.6, 2012
UMN Pharma Receives Approval to List on Tokyo Stock Exchange Mothers
読む UMN Pharma Receives Approval to List on Tokyo Stock Exchange Mothers
-
10.9, 2012
Memorandum of Understandings for the Co-development and Exclusive Commercialization Rights of UMN Pharma’s Recombinant Influenza HA Vaccine in South Korea with ILDONG PHARMACEUTICAL
-
9.13, 2012
UNIGEN, a UMN Pharma Subsidiary, Designated as Gifu Prefectural Government's “Subsidy for Promotion of Establishment of New Business Facilities”
-
3.29, 2012
Tatsuyoshi Hirano Takes Office as New CEO
-
3.13, 2012
Immunogenicity and Favorable Tolerability Observed in Phase II Clinical Trial for H5N1 Influenza Vaccine UMN-0501 (ASP7373)
-
3.6, 2012
UNIGEN Commences Construction of World-Class Biopharmaceutical Manufacturing Plant
読む UNIGEN Commences Construction of World-Class Biopharmaceutical Manufacturing Plant
-
2.22, 2012
Protein Sciences Licenses Proprietary expresSF+® Insect Cell Technology to Merck
読む Protein Sciences Licenses Proprietary expresSF+® Insect Cell Technology to Merck
-
2.14, 2012
UMN Pharma entered into a licensing agreement with Timo Vesikari, M.D. and Vesna Blazevic, Ph.D. that provides UMN Pharma with exclusive worldwide rights to develop and commercialize a novel norovirus VLP + rotavirus VP6 non-live injectable vaccine.
-
2.7, 2012
UNIGEN, a UMN Pharma Subsidiary, Selected in First Round of METI's FY 2011 “Subsidy for Domestic Location Promotion Projects”
-
12.21, 2011
Favorable Immunogenicity and Tolerability Observed in Phase I/II Clinical Trial for Seasonal Flu Vaccine UMN-0502 (ASP7374)
-
11.11, 2011
Administration of H5N1 Influenza Vaccine UMN-0501 (ASP7373) Completed in Phase II Clinical Trial
読む Administration of H5N1 Influenza Vaccine UMN-0501 (ASP7373) Completed in Phase II Clinical Trial
-
9.15, 2011
Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase I/II Clinical Trial
読む Administration of Seasonal Flu Vaccine UMN-0502 (ASP7374) Completed in Phase I/II Clinical Trial
-
7.1, 2011
UMN Pharma CEO, Shu-ichi Kanazashi, Makes Special-Session Presentation at 10th Int'l Bio Expo Japan, 2011
-
4.1, 2011
Akita Plant Commenced Operations: A new manufacturing technology development center
読む Akita Plant Commenced Operations: A new manufacturing technology development center
-
11.9, 2010
UMN Pharma secures exclusive rights from Protein Sciences Corporation to commercialize influenza vaccines in China, Hong Kong, Korea, Singapore and Taiwan
-
11.4, 2010
Protein Sciences Corporation and Emergent BioSolutions, Inc. reach agreement to end all litigation and entanglements between the companies
-
9.30, 2010
Astellas and UMN Pharma enter into the definitive agreement for UMN Pharma’s Cell Culture Based Influenza Vaccine Programs in Japan
-
8.17, 2010
Astellas Pharma Inc. and UMN Pharma Inc. Entered into a Memorandum of Understandings for UMN Pharma's Cell Culture Based Influenza Vaccine Program in Japan
-
4.20, 2010
UMN Pharma Confirms Immunogenicity and Safety of Avian Influenza A (H5N1) Vaccine Manufactured from Cell-Culture, UMN-0501 in Phase II Clinical Trial
-
4.16, 2010
API and UMN Pharma Announce Formulation Process Collaboration
読む API and UMN Pharma Announce Formulation Process Collaboration
-
1.26, 2010
IHI Corporation and UMN Pharma Announce Manufacturing Collaboration
読む IHI Corporation and UMN Pharma Announce Manufacturing Collaboration
-
10.5, 2009
UMN Pharma initiates phase II clinical trial for avian influenza A (H5N1) vaccine manufactured from cell-culture, UMN-0501.
-
6.29, 2009
Protein Sciences Corporation signs a contract which amounts to about 147 million dollars with U.S. Department of Health and Human Services for new way to make flu vaccine.
-
2.16, 2009
UMN Pharma Secures additional investment from IPEC.
-
2.13, 2009
UMN Pharma presents favorable results from Phase I/II study of UMN-0501 at World Health Organization (WHO) pandemic influenza meeting.
-
1.15, 2009
UMN Pharma Confirms Immunogenicity and Safety of UMN-0501 Pandemic Influenza Vaccine in Phase I/II Clinical Trials.
-
12.22, 2008
Relocation of Tokyo Head Office to Yokohama. Renamed as Yokohama Head Office.
-
8.22, 2008
UMN Pharma begins preparations for construction of a manufacturing facility for UMN-0501, a pandemic influenza vaccine manufactured using a novel cell culture technique.
-
6.18, 2008
UMN Pharma initiates phase I/II trials for pandemic influenza vaccine manufactured from cell-culture, UMN-0501.
-
6.10, 2008
UMN pandemic influenza vaccine, UMN-0501 designated as orphan drug.
読む UMN pandemic influenza vaccine, UMN-0501 designated as orphan drug.
-
4.30, 2008
UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine.
読む UMN Pharma acquires factory site in Akita for the manufacturing of pandemic influenza vaccine.
-
4.10, 2008
UMN Pharma announced initiation of phase I/II clinical trials for UMN-0501, UMN's pandemic influenza vaccine.
-
4.11, 2007
The result of a clinical study of FluBlØk (UMN-05) in the US is published in JAMA (The Journal of The American Medical Association).
-
2.21, 2007
UMN Pharma completes $18.9 million Series C financing round, with participation of 20 investors.
読む UMN Pharma completes $18.9 million Series C financing round, with participation of 20 investors.
-
8.29, 2006
UMN Pharma signs a license agreement of UMN-05 with Protein Sciences Corporation.
読む UMN Pharma signs a license agreement of UMN-05 with Protein Sciences Corporation.
-
2.3, 2006
UMN Pharma completes $7.5 million Series B-2 financing round, with participation of 11 investors.
読む UMN Pharma completes $7.5 million Series B-2 financing round, with participation of 11 investors.
-
10.17, 2005
UMN Pharma completes $1.1 million Series B-1 financing round, with participation of 3 venture capital firms.
-
7.22, 2005
UMN Pharma completes $0.9 million Series A round (second tranche), with participation of 2 venture capital firms.
-
12.31, 2004
UMN Pharma completes $0.9 million Series A round (first tranche), with participation of 2 venture capital firms.